Browse by goal
Peptides for Muscle Growth: The Evidence, and Its Limits
Growth-hormone peptides like CJC-1295 and Ipamorelin are used to chase muscle and body-composition gains by raising GH and IGF-1. Human evidence for real muscle or strength gains is limited, they are research-use-only and not approved for human use, and most are banned in tested competition.
Most discussed here: CJC-1295 · Ipamorelin
The compounds
Each one leads with how strong its human evidence is, and what that rating is based on.
- Prescription / GLP-1GHRH analogue (first 29 amino acids)
Sermorelin
Marketed to adults for sleep, body composition and aging. Approved use was growth hormone deficiency in children.
- Prescription / GLP-1GHRH analogue
Tesamorelin
Approved for reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy.
- Research peptidesSynthetic GHRH (1-29) analogue
CJC-1295
Investigated as a long-acting growth hormone-releasing hormone analogue to raise GH and IGF-I. Reached Phase 2 and was discontinued; never approved for any indication.
- Research peptidesPentapeptide growth hormone secretagogue
Ipamorelin
Investigated for postoperative ileus, reaching Phase 2 before being discontinued for insufficient efficacy. Marketed to consumers for growth hormone release, an application never approved anywhere.
The reading
- Research peptides
CJC-1295: With DAC and Without DAC, Explained
Two molecules share one name and behave nothing alike. One has a published multi-day half-life, the other has no human PK study. Plus legal status and sport bans.
Read guide→ - Research peptides
Ipamorelin: What the Clinical Record Shows
Ipamorelin is a growth hormone secretagogue that reached Phase 2 and stopped there. What the 1998 pharmacology found, and what the marketing leaves out.
Read guide→ - Research peptides
Peptide Stacking: What the Combination Research Covers
Stacking charts present combinations as if they were trial arms. What combination research exists, what it leaves out, and the questions worth asking first.
Read guide→ - Prescription
Sermorelin: What the Trials Studied, and Who They Studied It In
Approved in 1997 for children with growth hormone deficiency, discontinued in 2008 - and the FDA says not for safety reasons. What the trials actually studied.
Read guide→ - Prescription
Tesamorelin: The GHRH Peptide That Actually Cleared Approval
Same class as CJC-1295 and sermorelin, but with 26 randomised trials and an FDA approval - for visceral fat in people with HIV. That specificity is the point.
Read guide→